Current Report Filing (8-k)
June 13 2016 - 4:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 13, 2016
REVANCE THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
DELAWARE
|
|
001-36297
|
|
75-0551645
|
|
(State of
incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
Revance Therapeutics, Inc.
7555 Gateway Boulevard
Newark, California 94560
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (510) 742-3400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On June 13, 2016, Revance Therapeutics, Inc. issued a press release
announcing results from its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel. During a conference call and webcast scheduled to be held at 4:30 p.m. Eastern Daylight Time on June 13, 2016, Revance management will discuss the results from
the study. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference herein.
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
(d) Exhibits.
|
|
|
|
|
Number
|
|
Description
|
|
|
|
|
99.1
|
|
Press Release dated June 13, 2016.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: June 13, 2016
|
|
Revance Therapeutics, Inc.
|
|
|
|
|
|
|
|
By:
|
|
/s/ Lauren P. Silvernail
|
|
|
|
|
|
Lauren P. Silvernail
|
|
|
|
|
|
Chief Financial Officer and Chief Business Officer
|
EXHIBIT INDEX
|
|
|
|
|
Number
|
|
Description
|
|
|
|
|
99.1
|
|
Press Release dated June 13, 2016.
|
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024
